{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:40:00Z","timestamp":1792806000165,"version":"4.5.0"},"reference-count":104,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2018,7,16]],"date-time":"2018-07-16T00:00:00Z","timestamp":1531699200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1007\/s00198-018-4618-2","type":"journal-article","created":{"date-parts":[[2018,7,16]],"date-time":"2018-07-16T07:31:14Z","timestamp":1531726274000},"page":"2369-2387","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Phosphate wasting disorders in adults"],"prefix":"10.1007","volume":"29","author":[{"given":"G.","family":"Marcucci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Masi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Ferrar\u00ec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Haffner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.K.","family":"Javaid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Kamenick\u00fd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-Y.","family":"Reginster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Rizzoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.L.","family":"Brandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,7,16]]},"reference":[{"key":"4618_CR1","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1177\/0004563214521399","volume":"51","author":"P Manghat","year":"2014","unstructured":"Manghat P, Sodi R, Swaminathan R (2014) Phosphate homeostasis and disorders. Ann Clin Biochem 51:631\u2013656","journal-title":"Ann Clin Biochem"},{"key":"4618_CR2","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1542\/peds.2006-2023F","volume":"119","author":"MB Demay","year":"2007","unstructured":"Demay MB, Sabbagh Y, Carpenter TO (2007) Calcium and vitamin D: what is known about the effects on growing bone. Pediatrics 119:141\u2013144","journal-title":"Pediatrics"},{"key":"4618_CR3","first-page":"497","volume":"3","author":"S Fukumoto","year":"2014","unstructured":"Fukumoto S (2014) Phosphate metabolism and vitamin D. Bonekey Rep 3:497\u2013502","journal-title":"Bonekey Rep"},{"key":"4618_CR4","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s00590-014-1496-y","volume":"25","author":"V Pavone","year":"2015","unstructured":"Pavone V, Testa G, Gioitta Iachino S, Evola FR, Avondo S, Sessa G (2015) Hypophosphatemic rickets: etiology, clinical features and treatment. Eur J Orthop Surg Traumatol 25:221\u2013226","journal-title":"Eur J Orthop Surg Traumatol"},{"key":"4618_CR5","doi-asserted-by":"publisher","first-page":"F39","DOI":"10.1152\/ajprenal.00375.2003","volume":"287","author":"H Segawa","year":"2004","unstructured":"Segawa H, Kaneko I, Yamanaka S, Ito M, Kuwahata M, Inoue Y, Kato S, Miyamoto KI (2004) Intestinal Na-P(i) cotransporter adaptation to dietary P(i) content in vitamin D receptor null mice. Am J Physiol Renal Physiol 287:F39\u2013F47","journal-title":"Am J Physiol Renal Physiol"},{"key":"4618_CR6","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1172\/JCI108815","volume":"60","author":"R Rizzoli","year":"1977","unstructured":"Rizzoli R, Fleisch H, Bonjour JP (1977) Role of 1,25-dihydroxyvitamin D3 on intestinal phosphate absorption in rats with a normal vitamin D supply. J Clin Invest 60:639\u2013647","journal-title":"J Clin Invest"},{"key":"4618_CR7","doi-asserted-by":"publisher","first-page":"C429","DOI":"10.1152\/ajpcell.00331.2004","volume":"288","author":"P Capuano","year":"2005","unstructured":"Capuano P, Radanovic T, Wagner CA, Bacic D, Kato S, Uchiyama Y, St.-Arnoud R, Murer H, Biber J (2005) Intestinal and renal adaptation to a low-Pi diet of type II NaPi cotransporters in vitamin D receptor- and 1alpha OHase-deficient mice. Am J Physiol Cell Physiol 288:C429\u2013C434","journal-title":"Am J Physiol Cell Physiol"},{"key":"4618_CR8","doi-asserted-by":"publisher","first-page":"F647","DOI":"10.1152\/ajprenal.00354.2002","volume":"286","author":"SE Mulroney","year":"2004","unstructured":"Mulroney SE, Woda CB, Halaihel N, Louie B, McDonnell K, Schulkin J, Haramati A, Levi M (2004) Central control of renal sodium-phosphate (NaPi-2) transporters. Am J Physiol Renal Physiol 286:F647\u2013F652","journal-title":"Am J Physiol Renal Physiol"},{"key":"4618_CR9","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.bone.2012.05.015","volume":"51","author":"O Andrukhova","year":"2012","unstructured":"Andrukhova O, Zeitz U, Goetz R, Mohammadi M, Lanske B, Erben RG (2012) FGF23 acts directly on renal proximal tubules to induce phosphaturia through activation of the ERK1\/2-SGK1 signaling pathway. Bone 51:621\u2013628","journal-title":"Bone"},{"key":"4618_CR10","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1038\/ki.2008.643","volume":"75","author":"D Prie","year":"2009","unstructured":"Prie D, Urena Torres P, Friedlander G (2009) Latest findings in phosphate homeostasis. Kidney Int 75:882\u2013889","journal-title":"Kidney Int"},{"key":"4618_CR11","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s00223-012-9619-0","volume":"92","author":"MR Haussler","year":"2013","unstructured":"Haussler MR, Whitfield GK, Kaneko I, Haussler CA, Hsieh D, Hsieh JC, Jurutka PW (2013) Molecular mechanisms of vitamin D action. Calcif Tissue Int 92:77\u201398","journal-title":"Calcif Tissue Int"},{"key":"4618_CR12","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1159\/000366449","volume":"128","author":"P Delanaye","year":"2014","unstructured":"Delanaye P, Krzesinski JM, Warling X, Moonen M, Smelten N, M\u00e9dart L, Bruy\u00e8re O, Reginster JY, Pottel H, Cavalier E (2014) Clinical and biological determinants of sclerostin plasma concentration in hemodialysis patients. Nephron Clin Pract 128:127\u2013134","journal-title":"Nephron Clin Pract"},{"key":"4618_CR13","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.tem.2009.02.001","volume":"20","author":"S Fukumoto","year":"2009","unstructured":"Fukumoto S, Martin TJ (2009) Bone as an endocrine organ. Trends Endocrinol Metab 20:230\u2013236","journal-title":"Trends Endocrinol Metab"},{"key":"4618_CR14","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1006\/bbrc.2000.3696","volume":"277","author":"T Yamashita","year":"2000","unstructured":"Yamashita T, Yoshioka M, Itoh N (2000) Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain. Biochem Biophys Res Commun 277:494\u2013498","journal-title":"Biochem Biophys Res Commun"},{"key":"4618_CR15","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1093\/jmicro\/dfp032","volume":"58","author":"S Ubaidus","year":"2009","unstructured":"Ubaidus S, Li M, Sultana S, de Freitas PH, Oda K, Maeda T, Takagi R, Amizuka N (2009) FGF23 is mainly synthesized by osteocytes in the regularly distributed osteocytic lacunar canalicular system established after physiological bone remodeling. J Electron Microsc 58:381\u2013392","journal-title":"J Electron Microsc"},{"key":"4618_CR16","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1007\/s00223-015-9974-8","volume":"96","author":"L Masi","year":"2015","unstructured":"Masi L, Beltrami G, Ottanelli S, Franceschelli F, Gozzini A, Zonefrati R, Galli G, Ciuffi S, Mavilia C, Giusti F, Marcucci G, Cioppi F, Colli E, Fossi C, Franchi A, Casentini C, Capanna R, Brandi ML (2015) Human preosteoblastic cell culture from a patient with severe tumoral calcinosis-hyperphosphatemia due to a new GALNT3 gene mutation: study of in vitro mineralization. Calcif Tissue Int 96:438\u2013452","journal-title":"Calcif Tissue Int"},{"key":"4618_CR17","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.2106\/JBJS.H.00783","volume":"91","author":"L Masi","year":"2009","unstructured":"Masi L, Gozzini A, Franchi A, Campanacci D, Amedei A, Falchetti A, Franceschelli F, Marcucci G, Tanini A, Capanna R, Brandi ML (2009) A novel recessive mutation of fibroblast growth factor-23 in tumoral calcinosis. J Bone Joint Surg Am 91:1190\u20131198","journal-title":"J Bone Joint Surg Am"},{"key":"4618_CR18","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1152\/physrev.00002.2011","volume":"92","author":"A Martin","year":"2012","unstructured":"Martin A, David V, Quarles LD (2012) Regulation and function of the FGF23\/Klotho endocrine pathways. Physiol Rev 92:131\u2013155","journal-title":"Physiol Rev"},{"key":"4618_CR19","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1073\/pnas.0902006107","volume":"107","author":"R Goetz","year":"2010","unstructured":"Goetz R, Nakada Y, Hu MC, Kurosu H et al (2010) Isolated C-terminal tail of FGF23 alleviates hypophosphatemia by inhibiting FGF23-FGFR-Klotho complex formation. Proc Natl Acad Sci U S A 107:407\u2013412","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"4618_CR20","doi-asserted-by":"publisher","first-page":"6120","DOI":"10.1074\/jbc.C500457200","volume":"281","author":"H Kurosu","year":"2006","unstructured":"Kurosu H, Ogawa Y, Miyoshi M, Yamamoto M, Nandi A, Rosenblatt KP, Baum MG, Schiavi S, Hu MC, Moe OW, Kuro-o M (2006) Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem 281(10):6120\u20136123","journal-title":"J Biol Chem"},{"key":"4618_CR21","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1210\/jc.2004-1039","volume":"90","author":"SL Ferrari","year":"2005","unstructured":"Ferrari SL, Bonjour JP, Rizzoli R (2005) Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. J Clin Endocrinol Metab 90:1519\u20131524","journal-title":"J Clin Endocrinol Metab"},{"key":"4618_CR22","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1359\/JBMR.050718","volume":"20","author":"MT Collins","year":"2005","unstructured":"Collins MT, Lindsay JR, Jain A, Kelly MH, Cutler CM, Weinstein LS, Liu J, Fedarko NS, Winer KK (2005) Fibroblast growth factor-23 is regulated by 1alpha,25-dihydroxyvitamin D. J Bone Miner Res 20:1944\u20131950","journal-title":"J Bone Miner Res"},{"key":"4618_CR23","doi-asserted-by":"publisher","first-page":"3144","DOI":"10.1210\/jc.2006-0021","volume":"91","author":"DM Antoniucci","year":"2006","unstructured":"Antoniucci DM, Yamashita T, Portale AA (2006) Dietary phosphorus regulates serum fibroblast growth factor-23 concentrations in healthy men. J Clin Endocrinol Metab 91:3144\u20133149","journal-title":"J Clin Endocrinol Metab"},{"key":"4618_CR24","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1074\/jbc.M113.500850","volume":"289","author":"M Kawai","year":"2014","unstructured":"Kawai M, Kinoshita S, Shimba S, Ozono K, Michigami T (2014) Sympathetic activation induces skeletal Fgf23 expression in a circadian rhythm-dependent manner. J Biol Chem 289:1457\u20131466","journal-title":"J Biol Chem"},{"key":"4618_CR25","doi-asserted-by":"publisher","first-page":"E352","DOI":"10.1210\/jc.2010-0589","volume":"95","author":"TO Carpenter","year":"2010","unstructured":"Carpenter TO, Insogna KL, Zhang JH, Ellis B, Nieman S, Simpson C et al (2010) Circulating levels of soluble klotho and FGF23 in X-linked hypophosphatemia: circadian variance, effects of treatment, and relationship to parathyroid status. J Clin Endocrinol Metab 95:E352\u2013E357","journal-title":"J Clin Endocrinol Metab"},{"key":"4618_CR26","doi-asserted-by":"publisher","first-page":"2683","DOI":"10.1681\/ASN.2006070783","volume":"18","author":"T Kawata","year":"2007","unstructured":"Kawata T, Imanishi Y, Kobayashi K, Miki T, Arnold A, Inaba M, Nishizawa Y (2007) Parathyroid hormone regulates fibroblast growth factor-23 in a mouse model of primary hyperparathyroidism. J Am Soc Nephrol 18:2683\u20132688","journal-title":"J Am Soc Nephrol"},{"key":"4618_CR27","doi-asserted-by":"publisher","first-page":"F882","DOI":"10.1152\/ajprenal.00360.2010","volume":"299","author":"V Lavi-Moshayoff","year":"2010","unstructured":"Lavi-Moshayoff V, Wasserman G, Meir T, Silver J, Naveh-Many T (2010) PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: a bone parathyroid feedback loop. Am J Physiol Renal Physiol 299:F882\u2013F889","journal-title":"Am J Physiol Renal Physiol"},{"key":"4618_CR28","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.4065\/79.12.1508","volume":"79","author":"PJ Tebben","year":"2004","unstructured":"Tebben PJ, Singh RJ, Clarke BL, Kumar R (2004) Fibroblast growth factor 23, parathyroid hormone, and 1alpha,25-dihydroxyvitamin D in surgically treated primary hyperparathyroidism. Mayo Clin Proc 79:1508\u20131513","journal-title":"Mayo Clin Proc"},{"key":"4618_CR29","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s00223-017-0333-9","volume":"102","author":"ML Mace","year":"2018","unstructured":"Mace ML, Gravesen E, Nordholm A, Olgaard K, Lewin E (2018) Fibroblast growth factor (FGF) 23 regulates the plasma levels of parathyroid hormone in vivo through the FGF receptor in normocalcemia, but not in hypocalcemia. Calcif Tissue Int 102:85\u201392","journal-title":"Calcif Tissue Int"},{"key":"4618_CR30","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1002\/jbmr.2606","volume":"31","author":"SK Murali","year":"2016","unstructured":"Murali SK, Roschger P, Zeitz U, Klaushofer K, Andrukhova O, Erben RG (2016) FGF23 regulates bone mineralization in a 1,25(OH)2 D3 and Klotho-independent manner. J Bone Miner Res 31:129\u2013142","journal-title":"J Bone Miner Res"},{"key":"4618_CR31","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s00467-009-1273-z","volume":"25","author":"J Gattineni","year":"2010","unstructured":"Gattineni J, Baum M (2010) Regulation of phosphate transport by fibroblast growth factor 23 (FGF23): implications for disorders of phosphate metabolism. Pediatr Nephrol 25:591\u2013601","journal-title":"Pediatr Nephrol"},{"key":"4618_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00774-011-0340-2","volume":"30","author":"TO Carpenter","year":"2012","unstructured":"Carpenter TO (2012) The expanding family of hypophosphatemic syndromes. J Bone Miner Metab 30:1\u20139","journal-title":"J Bone Miner Metab"},{"key":"4618_CR33","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1038\/ng1868","volume":"38","author":"B Lorenz-Depiereux","year":"2006","unstructured":"Lorenz-Depiereux B, Bastepe M, Benet-Pages A, Amyere M, Wagenstaller J, Muller-Barth U, Badenhoop K, Kaiser SM, Rittmaster RS, Shlossberg AH, Olivares JL, Loris C, Ramos FJ, Glorieux F, Vikkula M, Juppner H, Strom TM (2006) DMP1 mutations in autosomal recessive hypophosphatemia implicate a bone matrix protein in the regulation of phosphate homeostasis. Nat Genet 38:1248\u20131250","journal-title":"Nat Genet"},{"key":"4618_CR34","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1210\/en.2007-1205","volume":"149","author":"A Martin","year":"2008","unstructured":"Martin A, David V, Laurence JS, Schwarz PM, Lafer EM, Hedge AM, Rowe PSN (2008) Degradation of MEPE, DMP1, and release of SIBLING ASARM-peptides (minhibins): ASARM-peptide(s) are directly responsible for defective mineralization in HYP. Endocrinology 149:1757\u20131772","journal-title":"Endocrinology"},{"key":"4618_CR35","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1007\/s00467-016-3505-3","volume":"32","author":"D Haffner","year":"2017","unstructured":"Haffner D, Leifheit-Nestler M (2017) Extrarenal effects of FGF23. Pediatr Nephrol 32:753\u2013765","journal-title":"Pediatr Nephrol"},{"key":"4618_CR36","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1002\/jbmr.1923","volume":"28","author":"M Wolf","year":"2013","unstructured":"Wolf M, Koch TA, Bregman DB (2013) Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women. J Bone Miner Res 28:1793\u20131803","journal-title":"J Bone Miner Res"},{"key":"4618_CR37","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1359\/JBMR.0301264","volume":"19","author":"T Shimada","year":"2004","unstructured":"Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, Fujita T, Nakahara K, Fukumoto S, Yamashita T (2004) FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 19:429\u2013435","journal-title":"J Bone Miner Res"},{"key":"4618_CR38","doi-asserted-by":"crossref","unstructured":"Dadoniene J, Miglinas M, Miltiniene D, Vajauskas D, Seinin D, Butenas P, Kacergius T (2016) Tumour-induced osteomalacia: a literature review and a case report World J Surg Oncol 14","DOI":"10.1186\/s12957-015-0763-7"},{"key":"4618_CR39","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1373\/clinchem.2013.206649","volume":"60","author":"J Donate-Correa","year":"2014","unstructured":"Donate-Correa J, Muros de Fuentes M, Mora-Fern\u00e1ndez C, Navarro-Gonz\u00e1lez JF (2014) Pathophysiological implications of fibroblast growth factor-23 and Klotho and their potential role as clinical biomarkers. Clin Chem 60:933\u2013940","journal-title":"Clin Chem"},{"key":"4618_CR40","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1007\/s00223-017-0307-y","volume":"101","author":"JC Souberbielle","year":"2017","unstructured":"Souberbielle JC, Pri\u00e9 D, Piketty ML, Rothenbuhler A, Delanaye P, Chanson P, Cavalier E (2017) Evaluation of a new fully automated assay for plasma intact FGF23. Calcif Tissue Int 101:510\u2013518","journal-title":"Calcif Tissue Int"},{"key":"4618_CR41","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1002\/jbmr.340","volume":"26","author":"TO Carpenter","year":"2011","unstructured":"Carpenter TO, Imel EA, Holm IA et al (2011) A clinician\u2019s guide to X-linked hypophosphatemia. J Bone Miner Res 26:1381\u20131388","journal-title":"J Bone Miner Res"},{"key":"4618_CR42","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s40618-014-0202-6","volume":"38","author":"G Marcucci","year":"2015","unstructured":"Marcucci G, Cianferotti L, Beck-Peccoz P, Capezzone M, Cetani F, Colao A, Dav\u00ec MV, degli Uberti E, Del Prato S, Elisei R, Faggiano A, Ferone D, Foresta C, Fugazzola L, Ghigo E, Giacchetti G, Giorgino F, Lenzi A, Malandrino P, Mannelli M, Marcocci C, Masi L, Pacini F, Opocher G, Radicioni A, Tonacchera M, Vigneri R, Zatelli MC, Brandi ML (2015) Rare diseases in clinical endocrinology: a taxonomic classification system. J Endocrinol Investig 38:193\u2013259","journal-title":"J Endocrinol Investig"},{"key":"4618_CR43","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/ng1095-130","volume":"11","author":"The HYP Consortium","year":"1995","unstructured":"The HYP Consortium (1995) A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. Nat Genet 11:130\u2013136","journal-title":"Nat Genet"},{"key":"4618_CR44","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s00431-010-1382-5","volume":"170","author":"US Alon","year":"2011","unstructured":"Alon US (2011) Clinical practice. Fibroblast growth factor (FGF)23: a new hormone. Eur J Pediatr 170:545\u2013554","journal-title":"Eur J Pediatr"},{"key":"4618_CR45","doi-asserted-by":"publisher","first-page":"E38","DOI":"10.1152\/ajpendo.00008.2006","volume":"291","author":"S Liu","year":"2006","unstructured":"Liu S, Zhou J, Tang W, Jiang X, Rowe DW, Quarles LD (2006) Pathogenic role of FGF23 in Hyp mice. Am J Physiol Endocrinol Metab 291:E38\u2013E49","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"4618_CR46","doi-asserted-by":"publisher","first-page":"F783","DOI":"10.1152\/ajprenal.00304.2010","volume":"300","author":"V David","year":"2011","unstructured":"David V, Martin A, Hedge AM, Drezner MK, Rowe PS (2011) ASARM peptides: PHEX-dependent and -independent regulation of serum phosphate. Am J Physiol Renal Physiol 300:F783\u2013F791","journal-title":"Am J Physiol Renal Physiol"},{"key":"4618_CR47","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s00223-009-9270-6","volume":"85","author":"G Liang","year":"2009","unstructured":"Liang G, Katz LD, Insogna KL, Carpenter TO, Macica CM (2009) Survey of the enthesopathy of X linked hypophosphatemia and its characterization in Hyp mice. Calcif Tiss Int 85:235\u2013246","journal-title":"Calcif Tiss Int"},{"key":"4618_CR48","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1111\/j.1601-0825.2006.01326.x","volume":"13","author":"C Chaussain-Miller","year":"2007","unstructured":"Chaussain-Miller C, Sinding C, Septier D, Wolikow M, Goldberg M, Garabedian M (2007) Dentin structure in familial hypophosphatemic rickets: benefits of vitamin D and phosphate treatment. Oral Dis 13:482\u2013489","journal-title":"Oral Dis"},{"key":"4618_CR49","doi-asserted-by":"publisher","first-page":"R13","DOI":"10.1530\/EC-13-0103","volume":"3","author":"A Linglart","year":"2014","unstructured":"Linglart A, Biosse-Duplan M, Briot K, Chaussain C, Esterle L, Guillaume-Czitrom S, Kamenicky P, Nevoux J, Pri\u00e9 D, Rothenbuhler A, Wicart P, Harvengt P (2014) Therapeutic management of hypophosphatemic rickets from infancy to adulthood. Endocr Connect 3:R13\u2013R30","journal-title":"Endocr Connect"},{"issue":"4","key":"4618_CR50","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1007\/s10157-017-1510-x","volume":"22","author":"Akira Iguchi","year":"2017","unstructured":"Iguchi A, Yamamoto S, Yamazaki M, Tasaki K, Suzuki Y, Kazama JJ, Narita I (2017) Effect of ferric citrate hydrate on FGF23 and PTH levels in patients with non-dialysis-dependent chronic kidney disease with normophosphatemia and iron deficiency. Clin Exp Nephrol. \n                    https:\/\/doi.org\/10.1007\/s10157-017-1510-x","journal-title":"Clinical and Experimental Nephrology"},{"issue":"4","key":"4618_CR51","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/j.bone.2009.06.017","volume":"45","author":"Yuichiro Shimizu","year":"2009","unstructured":"Shimizu Y, Tada Y, Yamauchi M, Okamoto T, Suzuki H, Ito N, Fukumoto S, Sugimoto T, Fujita T (2009) Hypophosphatemia induced by intravenous administration of saccharated ferric oxide: another form of FGF23-related hypophosphatemia. Bone. 45:814\u20136","journal-title":"Bone"},{"key":"4618_CR52","doi-asserted-by":"publisher","first-page":"120","DOI":"10.4248\/BR201302002","volume":"28","author":"X Huang","year":"2013","unstructured":"Huang X, Jiang Y, Xia W (2013) FGF23 and phosphate wasting disorders. Bone 28:120\u2013132","journal-title":"Bone"},{"key":"4618_CR53","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1681\/ASN.2005050573","volume":"16","author":"EA Imel","year":"2005","unstructured":"Imel EA, Econs MJ (2005) Fibroblast growth factor 23: roles in health and disease. J Am Soc Nephrol 16:2565\u20132575","journal-title":"J Am Soc Nephrol"},{"key":"4618_CR54","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1210\/jcem.82.2.3765","volume":"82","author":"MJ Econs","year":"1997","unstructured":"Econs MJ, McEnery PT (1997) Autosomal dominant hypophosphatemic rickets\/osteomalacia: clinical characterization of a novel renal phosphate-wasting disorder. J Clin Endocrinol Metab 82:674\u2013681","journal-title":"J Clin Endocrinol Metab"},{"key":"4618_CR55","doi-asserted-by":"publisher","first-page":"3541","DOI":"10.1210\/jc.2011-1239","volume":"96","author":"EA Imel","year":"2011","unstructured":"Imel EA, Peacock M, Gray AK, Padgett LR, Hui SL, Econs MJ (2011) Iron modifies plasma FGF23 differently in autosomal dominant hypophosphatemic rickets and healthy humans. J Clin Endocrinol Metab 96:3541\u20133549","journal-title":"J Clin Endocrinol Metab"},{"key":"4618_CR56","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1359\/jbmr.070107","volume":"22","author":"EA Imel","year":"2007","unstructured":"Imel EA, Hui SL, Econs MJ (2007) FGF23 concentrations vary with disease status in autosomal dominant hypophosphatemic rickets. J Bone Miner Res 22:520\u2013526","journal-title":"J Bone Miner Res"},{"key":"4618_CR57","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.ajhg.2010.01.010","volume":"86","author":"V Levy-Litan","year":"2010","unstructured":"Levy-Litan V, Hershkovitz E, Avizov L, Leventhal N, Bercovich D, Chalifa-Caspi V, Manor E, Buriakovsky S, Hadad Y, Goding J, Parvari R (2010) Autosomal-recessive hypophosphatemic rickets is associated with an inactivation mutation in the ENPP1 gene. Am J Hum Genet 86:273\u2013278","journal-title":"Am J Hum Genet"},{"key":"4618_CR58","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1086\/499410","volume":"78","author":"B Lorenz-Depiereux","year":"2006","unstructured":"Lorenz-Depiereux B, Benet-Pages A, Eckstein G, Tenenbaum-Rakover Y, Wagenstaller J, Tiosano D, Gershoni-Baruch R, Albers N, Lichtner P, Schnabel D, Hochberg Z', Strom TM (2006) Hereditary hypophosphatemic rickets with hypercalciuria is caused by mutations in the sodium-phosphate cotransporter gene SLC34A3. Am J Hum Genet 78:193\u2013201","journal-title":"Am J Hum Genet"},{"key":"4618_CR59","doi-asserted-by":"publisher","first-page":"C1316","DOI":"10.1152\/ajpcell.00314.2011","volume":"302","author":"S Haito-Sugino","year":"2012","unstructured":"Haito-Sugino S, Ito M, Ohi A, Shiozaki Y, Kangawa N, Nishiyama T, Aranami F, Sasaki S, Mori A, Kido S, Tatsumi S, Segawa H, Miyamoto KI (2012) Processing and stability of type IIc sodium-dependent phosphate cotransporter mutations in patients with hereditary hypophosphatemic rickets with hypercalciuria. Am J Physiol Cell Physiol 302:C1316\u2013C1330","journal-title":"Am J Physiol Cell Physiol"},{"key":"4618_CR60","doi-asserted-by":"publisher","first-page":"F371","DOI":"10.1152\/ajprenal.00090.2008","volume":"295","author":"G Jaureguiberry","year":"2008","unstructured":"Jaureguiberry G, Carpenter TO, Forman S, Harald J\u00fcppner H, Bergwitz C (2008) A novel missense mutation in SLC34A3 that causeshereditary hypophosphatemic rickets with hypercalciuria inhumans identifies threonine 137 as an important determinant ofsodium-phosphate cotransport in NaPi-IIc. Am J Physiol Renal Physiol 295:F371\u2013F379","journal-title":"Am J Physiol Renal Physiol"},{"key":"4618_CR61","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1172\/JCI18399","volume":"112","author":"M Riminucci","year":"2003","unstructured":"Riminucci M, Collins MT, Fedarko NS, Cherman N, Corsi A, White KE, Waguespack S, Gupta A, Hannon T, Econs MJ, Bianco P, Gehron Robey P (2003) FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J Clin Invest 112:683\u2013692","journal-title":"J Clin Invest"},{"key":"4618_CR62","first-page":"367","volume":"2","author":"JY Lee","year":"2013","unstructured":"Lee JY, Imel EA (2013) The changing face of hypophosphatemic disorders in the FGF-23 era. Pediatr Endocrinol Rev 2:367\u2013379","journal-title":"Pediatr Endocrinol Rev"},{"key":"4618_CR63","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1002\/jbmr.1546","volume":"27","author":"N Bhattacharyya","year":"2012","unstructured":"Bhattacharyya N, Wiench M, Dumitrescu C, Connolly BM, Bugge TH, Patel HV, Gafni RI, Cherman N, Cho M, Hager GL, Collins MT (2012) Mechanism of FGF23 processing in fibrous dysplasia. J Bone Miner Res 27:1132\u20131141","journal-title":"J Bone Miner Res"},{"key":"4618_CR64","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/00000478-200401000-00001","volume":"28","author":"AL Folpe","year":"2004","unstructured":"Folpe AL, Fanburg-Smith JC, Billings SD, Bisceglia M, Bertoni F, Cho JY, Econs MJ, Inwards CY, Jan de Beur SM, Mentzel T, Montgomery E, Michal M, Miettinen M, Mills SE, Reith JD, O'Connell JX, Rosenberg AE, Rubin BP, Sweet DE, Vinh TN, Wold LE, Wehrli BM, White KE, Zaino RJ, Weiss SW (2004) Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol 28:1\u201330","journal-title":"Am J Surg Pathol"},{"key":"4618_CR65","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s12891-015-0496-3","volume":"16","author":"Z Sun","year":"2015","unstructured":"Sun Z, Jin J, Qiu G, Gao P, Liu Y (2015) Surgical treatment of tumor-induced osteomalacia: a retrospective review of 40 cases with extremity tumors. BMC Musculoskelet Disord 16:43","journal-title":"BMC Musculoskelet Disord"},{"key":"4618_CR66","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1097\/RLU.0b013e31818866bf","volume":"33","author":"M Duet","year":"2008","unstructured":"Duet M, Kerkeni S, Sfar R, Bazille C, Liot\u00e9 F, Orcel P (2008) Clinical impact of somatostatin receptor scintigraphy in the management of tumor-induced osteomalacia. Clin Nucl Med 33:752\u2013756","journal-title":"Clin Nucl Med"},{"key":"4618_CR67","first-page":"729387","volume":"2014","author":"AH Hautmann","year":"2014","unstructured":"Hautmann AH, Schroeder J, Wild P, Hautmann MG, Huber E, Hoffstetter P et al (2014) Tumor-induced osteomalacia: increased level of FGF-23 in a patient with a phosphaturic mesenchymal tumor at the tibia expressing periostin. Case Rep Endocrinol 2014:729387","journal-title":"Case Rep Endocrinol"},{"key":"4618_CR68","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1159\/000184216","volume":"44","author":"H Stark","year":"1986","unstructured":"Stark H, Eisenstein B, Tieder M, Rachmel A, Alpert G (1986) Direct measurement of TP\/ GFR: a simple and reliable parameter of renal phosphate handling. Nephron 44:125\u2013128","journal-title":"Nephron"},{"key":"4618_CR69","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1016\/j.bone.2008.02.014","volume":"42","author":"I Endo","year":"2008","unstructured":"Endo I, Fukumoto S, Ozono K, Namba N, Tanaka H, Inoue D, Minagawa M, Sugimoto T, Yamauchi M, Michigami T, Matsumoto T (2008) Clinical usefulness of measurement of fibroblast growth factor 23 (FGF23) in hypophosphatemicpatients: proposal of diagnostic criteria using FGF23 measurement. Bone 42:1235\u20131239","journal-title":"Bone"},{"key":"4618_CR70","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1507\/endocrj.K10E-257","volume":"58","author":"JM Igaki","year":"2011","unstructured":"Igaki JM, Yamada M, Yamazaki Y, Koto S, Izawa M, Ariyasu D, Suzuki E, Hasegawa H, Hasegawa Y (2011) High iFGF23 level despite hypophosphatemia is one of the clinical indicators to make diagnosis of XLH. Endocr J 58:647\u2013655","journal-title":"Endocr J"},{"key":"4618_CR71","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1172\/JCI111900","volume":"75","author":"RM Harrell","year":"1985","unstructured":"Harrell RM, Lyles KW, Harrelson JM, Friedman NE, Drezner MK (1985) Healing of bone disease in X-linked hypophosphatemic rickets\/osteomalacia. Induction and maintenance with phosphorus and calcitriol. J Clin Invest 75:1858\u20131868","journal-title":"J Clin Invest"},{"key":"4618_CR72","doi-asserted-by":"publisher","first-page":"5358","DOI":"10.1210\/en.2005-0777","volume":"146","author":"F Perwad","year":"2005","unstructured":"Perwad F, Azam N, Zhang MY et al (2005) Dietary and serum phosphorus regulate fibroblast growth factor 23 expression and 1,25-dihydroxyvitamin D metabolism in mice. Endocrinology 146:5358\u20135364","journal-title":"Endocrinology"},{"key":"4618_CR73","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1067\/mpd.2001.108955","volume":"138","author":"GI Baroncelli","year":"2001","unstructured":"Baroncelli GI, Bertelloni S, Ceccarelli C, Saggese G (2001) Effect of growth hormone treatment on final height, phosphate metabolism, and bone mineral density in children with X-linked hypophosphatemic rickets. J Pediatr 138:236\u2013243 20","journal-title":"J Pediatr"},{"key":"4618_CR74","doi-asserted-by":"publisher","first-page":"e593","DOI":"10.1542\/peds.113.6.e593","volume":"113","author":"D Haffner","year":"2004","unstructured":"Haffner D, Nissel R, Wuh E, Mehls O (2004) Effects of growth hormone treatment on body proportions and final height among small children with X-linked hypophosphatemic rickets. Pediatrics 113:e593\u2013e596","journal-title":"Pediatrics"},{"key":"4618_CR75","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/S0022-3476(95)70070-6","volume":"127","author":"G Saggese","year":"1995","unstructured":"Saggese G, Baroncelli G, Bertelloni S, Perri G (1995) Long-term growth hormone treatment in children with renal hypophosphatemic rickets: effects on growth, mineral metabolism, and bone density. J Pediatr 127:395\u2013402","journal-title":"J Pediatr"},{"key":"4618_CR76","doi-asserted-by":"publisher","first-page":"E2097","DOI":"10.1210\/jc.2011-0399","volume":"96","author":"M \u017divi\u010dnjak","year":"2011","unstructured":"\u017divi\u010dnjak M, Schnabel D, Staude H, Even G, Marx M, Beetz R, Holder M, Billing H, Fischer DC, Rabl W, Schumacher M, Hiort O, Haffner D, Hypophosphatemic Rickets Study Group of the Arbeitsgemeinschaft f\u00fcr P\u00e4diatrische Endokrinologie and Gesellschaft f\u00fcr P\u00e4diatrische Nephrologie (2011) Three-year growth hormone treatment in short children with X-linked hypophosphatemic rickets: effects on linear growth and body disproportion. J Clin Endocrinol Metab 96:E2097\u2013E2105","journal-title":"J Clin Endocrinol Metab"},{"key":"4618_CR77","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s00467-017-3820-3","volume":"33","author":"N Meyerhoff","year":"2018","unstructured":"Meyerhoff N, Haffner D, Staude H, W\u00fchl E, Marx M, Beetz R, Querfeld U, Holder M, Billing H, Rabl W, Schr\u00f6der C, Hiort O, Br\u00e4mswig JH, Richter-Unruh A, Schnabel D, \u017divi\u010dnjak M, Hypophosphatemic Rickets Study Group of the \u201cDeutsche Gesellschaft f\u00fcr Kinderendokrinologie und -diabetologie\u201d and \u201cGesellschaft f\u00fcr P\u00e4diatrische Nephrologie\u201d (2018) Effects of growth hormone treatment on adult height in severely short children with X-linked hypophosphatemic rickets. Pediatr Nephrol 33:447\u2013456","journal-title":"Pediatr Nephrol"},{"key":"4618_CR78","first-page":"50","volume":"38","author":"KS Eyres","year":"1993","unstructured":"Eyres KS, Brown J, Douglas DL (1993) Osteotomy and intramedullary nailing for the correction of progressive deformity in vitamin D-resistant hypophosphatemic rickets. J R Coll Surg Edinb 38:50\u201354","journal-title":"J R Coll Surg Edinb"},{"key":"4618_CR79","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1093\/ndt\/gfr645","volume":"27","author":"H Komaba","year":"2011","unstructured":"Komaba H, Koizumi M, Tanaka H et al (2011) Effects of cinacalcet treatment on serum soluble Klotho levels in haemodialysis patients with secondary hyperparathyroidism. Nephrol Dial Transplant 27:1967\u20131969","journal-title":"Nephrol Dial Transplant"},{"key":"4618_CR80","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1124\/jpet.103.057273","volume":"308","author":"EF Nemeth","year":"2004","unstructured":"Nemeth EF, Heaton WH, Miller M, Fox J, Balandrin MF, Van Wagenen BC, Colloton M, Karbon W, Scherrer J, Shatzen E, Rishton G, Scully S, Qi M, Harris R, Lacey D, Martin D (2004) Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl. J Pharmacol Exp Ther 308:627\u2013635","journal-title":"J Pharmacol Exp Ther"},{"key":"4618_CR81","doi-asserted-by":"publisher","first-page":"658","DOI":"10.2215\/CJN.04981107","volume":"3","author":"US Alon","year":"2008","unstructured":"Alon US, Levy-Olomucki R, Moore WV, Stubbs J, Liu S, Quarles LD (2008) Calcimimetics as an adjuvant treatment for familial hypophosphatemic rickets. Clin J Am Soc Nephrol 3:658\u2013664","journal-title":"Clin J Am Soc Nephrol"},{"key":"4618_CR82","doi-asserted-by":"publisher","first-page":"274","DOI":"10.14310\/horm.2002.1277","volume":"9","author":"MP Yavropoulou","year":"2010","unstructured":"Yavropoulou MP, Kotsa K, Gotzamani Psarrakou A, Papazisi A, Tranga T, Ventis S, Yovos JG (2010) Cinacalcet in hyperparathyroidism secondary to X-linked hypophosphatemic rickets: case report and brief literature review. Hormones (Athens) 9:274\u2013278","journal-title":"Hormones (Athens)"},{"key":"4618_CR83","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.bone.2017.06.019","volume":"103","author":"M Leifheit-Nestler","year":"2017","unstructured":"Leifheit-Nestler M, Kucka J, Yoshizawa E, Behets G, D'Haese P, Bergen C, Meier M, Fischer DC, Haffner D (2017) Comparison of calcimimetic R568 and calcitriol in mineral homeostasis in the Hyp mouse, a murine homolog of X-linked hypophosphatemia. Bone 103:224\u2013232","journal-title":"Bone"},{"key":"4618_CR84","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1056\/NEJMc1010928","volume":"364","author":"ES Liu","year":"2011","unstructured":"Liu ES, Carpenter TO, Gundberg CM et al (2011) Calcitonin administration in X-linked hypophosphatemia. N Engl J Med 364:1678\u20131680","journal-title":"N Engl J Med"},{"key":"4618_CR85","unstructured":"Data available: European agency medicine (2012) Calcitonin. \n                    http:\/\/www.ema.europa.eu\/ema\/index.jspcurl=pages\/medicines\/human\/referrals\/Calcitonin\/human_referral_000319.jsp&mid=WC0b01ac0580024e99\n                    \n                  . Accessed 31 May 2018"},{"key":"4618_CR86","unstructured":"FDA (2015) Questions and Answers: Changes to the Indicated Population for Miacalcin (calcitonin-salmon). \n                    https:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm388641.htm\n                    \n                  . Accessed 31 May 2018"},{"key":"4618_CR87","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1359\/jbmr.080417","volume":"23","author":"Y Yamazaki","year":"2008","unstructured":"Yamazaki Y, Tamada T, Kasai N, Urakawa I, Aono Y, Hasegawa H, Fujita T, Kuroki R, Yamashita T, Fukumoto S, Shimada T (2008) Anti-FGF23 neutralizing antibodies show the physiological role and structural features of FGF23. J Bone Miner Res 23:1509\u20131518","journal-title":"J Bone Miner Res"},{"key":"4618_CR88","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1002\/jbmr.275","volume":"26","author":"Y Aono","year":"2011","unstructured":"Aono Y, Hasegawa H, Yamazaki Y, Shimada T, Fujita T, Yamashita T, Fukumoto S (2011) Anti-FGF23 neutralizing antibodies ameliorate muscle weakness and decreased spontaneous movement of Hyp mice. J Bone Miner Res 26:803\u2013810","journal-title":"J Bone Miner Res"},{"key":"4618_CR89","unstructured":"ClinicalTrials.gov\n                    \n                   identifiers NCT00830674"},{"key":"4618_CR90","unstructured":"ClinicalTrials.gov\n                    \n                   identifiers NCT01340482"},{"key":"4618_CR91","unstructured":"ClinicalTrials.gov\n                    \n                   identifiers NCT01571596"},{"key":"4618_CR92","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1172\/JCI72829","volume":"124","author":"EA Imel","year":"2014","unstructured":"Carpenter TO, Imel EA, Ruppe MD, Weber TJ, Klausner MA, Wooddell MM, Kawakami T, Ito T, Zhang X, Humphrey J, Insogna KL, Peacock M (2014) Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia. J Clin Invest 124:1587\u20131597","journal-title":"J Clin Invest"},{"issue":"uppl 1","key":"4618_CR93","first-page":"SU0169","volume":"28","author":"X Zhang","year":"2013","unstructured":"Zhang X, Carpenter T, Imel E et al (2013) Pharmacokinetics and pharmacodynamics of a human monoclonal anti-FGF23 antibody (KRN23) after single-dose administration to patients with X-linked hypophosphatemia. J Bone Miner Res 28(uppl 1):SU0169","journal-title":"J Bone Miner Res"},{"key":"4618_CR94","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1210\/jc.2015-1551","volume":"10","author":"EA Imel","year":"2015","unstructured":"Imel EA, Zhang X, Ruppe MD, Weber TJ, Klausner MA, Ito T, Vergeire M, Humphrey JS, Glorieux FH, Portale AA, Insogna K, Peacock M, Carpenter TO (2015) Prolonged correction of serum phosphorus in adults with X-linked hypophosphatemia using monthly doses of KRN23. J Clin Endocrinol Metab 10:2565\u20132573","journal-title":"J Clin Endocrinol Metab"},{"key":"4618_CR95","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.bonr.2016.05.004","volume":"13","author":"MD Ruppe","year":"2016","unstructured":"Ruppe MD, Zhang X, Imel EA, Weber TJ, Klausner MA, Ito T, Vergeire M, Humphrey JS, Glorieux FH, Portale AA, Insogna K, Peacock M, Carpenter TO (2016) Effect of four monthly doses of a human monoclonal anti-FGF23 antibody (KRN23) on quality of life in X-linked hypophosphatemia. Bone Rep 13:158\u2013162","journal-title":"Bone Rep"},{"issue":"3","key":"4618_CR96","doi-asserted-by":"publisher","first-page":"17044","DOI":"10.1038\/nrdp.2017.44","volume":"13","author":"S Minisola","year":"2017","unstructured":"Minisola S, Peacock M, Fukumoto S, Cipriani C, Pepe J, Tella HT, Collins MT (2017) Tumor-induced osteomalacia. Nat Rev Dis Primers 13(3):17044","journal-title":"Nat Rev Dis Primers"},{"key":"4618_CR97","doi-asserted-by":"publisher","first-page":"2374","DOI":"10.1210\/jc.2006-2865","volume":"92","author":"A Khosravi","year":"2007","unstructured":"Khosravi A, Cutler CM, Kelly MH, Chang R, Royal RE, Sherry RM, Wodajo FM, Fedarko NS, Collins MT (2007) Determination of the elimination half-life of fibroblast growth factor-23. Journal of Clinical Endocrinology & Metabolism 92:2374\u20132377","journal-title":"Journal of Clinical Endocrinology & Metabolism"},{"key":"4618_CR98","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1111\/j.1365-2265.1992.tb02342.x","volume":"37","author":"JN Harvey","year":"1992","unstructured":"Harvey JN, Gray C, Belchetz PE (1992) Oncogenous osteomalacia and malignancy. Clin Endocrinol 37:379\u2013382","journal-title":"Clin Endocrinol"},{"key":"4618_CR99","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1056\/NEJMc070347","volume":"357","author":"E Hesse","year":"2007","unstructured":"Hesse E, Rosenthal H, Bastian L (2007) Radiofrequency ablation of a tumor causing oncogenic osteomalacia. N Engl J Med 357:422\u2013424","journal-title":"N Engl J Med"},{"key":"4618_CR100","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1359\/jbmr.070304","volume":"22","author":"JL Geller","year":"2007","unstructured":"Geller JL, Khosravi A, Kelly MH, Riminucci M, Adams JS, Collins MT (2007) Cinacalcet in the management of tumor-induced osteomalacia. J Bone Miner Res 22:931\u2013937","journal-title":"J Bone Miner Res"},{"key":"4618_CR101","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1530\/EJE-07-0779","volume":"158","author":"G Boekel van","year":"2008","unstructured":"van Boekel G, Ruinemans-Koerts J, Joosten F, Dijkhuizen P, van Sorge A, de Boer H (2008) Tumor producing fibroblast growth factor 23 localized by two-staged venous sampling. Eur J Endocrinol 158:431\u2013437","journal-title":"Eur J Endocrinol"},{"key":"4618_CR102","doi-asserted-by":"crossref","unstructured":"Carpenter TO, Miller P, Weber T, et al. (2017) Effects of KRN23, and anti- FGF23 antibody, in patients with tumor induced osteomalacia and epidermal nevus syndrome: results from an ongoing phase 2 study. In: Annual Meeting of the American Society for Bone and Mineral Research 1098. Bone Reports 7,90\u201397 96 D","DOI":"10.1016\/j.bonr.2017.09.002"},{"key":"4618_CR103","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1007\/s00223-015-0029-y","volume":"98","author":"S Fukumoto","year":"2016","unstructured":"Fukumoto S (2016) FGF23-FGF receptor\/Klotho pathway as a new drug target for disorders of bone and mineral metabolism. Calcif Tissue Int 98:334\u2013340","journal-title":"Calcif Tissue Int"},{"issue":"Suppl 1","key":"4618_CR104","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1186\/1750-1172-7-S1-S4","volume":"7","author":"MT Collins","year":"2012","unstructured":"Collins MT, Singer FR, Eugster E (2012) McCune-Albright syndrome and the extraskeletal manifestations of fibrous dysplasia. Orphanet J Rare Dis 7(Suppl 1):S4","journal-title":"Orphanet J Rare Dis"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00198-018-4618-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-018-4618-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-018-4618-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,15]],"date-time":"2019-07-15T19:14:45Z","timestamp":1563218085000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00198-018-4618-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,16]]},"references-count":104,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["4618"],"URL":"https:\/\/doi.org\/10.1007\/s00198-018-4618-2","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,16]]},"assertion":[{"value":"22 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"MKJ is a member of the Kyowa Kirin Hakin Advisory Board and has received honoraria and research grants from Kyowa Kirin Hakin. MLB is a consultant for Alexion, Bruno Farmaceutici, Shire, Servier, and Kyowa Kirin and received academic grants and\/or speaker fees from Abiogen, Alexion, Amgen, Bruno Farmaceutici, Eli Lilly, Kyowa Kirin, MSD, NPS, Servier, Shire, and SPA. She has received honoraria from Amgen, Bruno Farmaceutici, and Kyowa Kirin. The other authors declare that they have no conflict of interest or disclosures.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"For this type of study, formal consent is not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights"}}]}}